scholarly journals One-Year Effectiveness and Safety of Dupilumab Treatment for Moderate-to-Severe Atopic Dermatitis in Korean Patients: A Real-World Retrospective Analysis

2022 ◽  
Vol 14 (1) ◽  
pp. 117
Author(s):  
Hanjae Lee ◽  
Bo Ri Kim ◽  
Kyu Han Kim ◽  
Dong Hun Lee ◽  
Jung Im Na
Keyword(s):  
Atopic Dermatitis ◽  
Retrospective Analysis ◽  
Real World ◽  
Severe Atopic Dermatitis ◽  
Korean Patients ◽  
One Year

scholarly journals Real‐world experience of dupilumab in the treatment of moderate‐to‐severe atopic dermatitis

2020 ◽  
Vol 59 (10) ◽  
Author(s):  
Nicole S. Kim ◽  
Khalad Maliyar ◽  
Luciana Oliveira ◽  
Ashley O’Toole ◽  
Melinda J. Gooderham
Keyword(s):  
Atopic Dermatitis ◽  
Real World ◽  
Severe Atopic Dermatitis

15260 Dupilumab treatment in adult patients with moderate to severe atopic dermatitis: A real-world single-center experience from Turkey

2020 ◽  
Vol 83 (6) ◽  
pp. AB144
Author(s):  
Andac Salman ◽  
Meryem Aktas ◽  
Esra Özkürkçü ◽  
Gonca Saraç ◽  
Oktay Taskapan ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Real World ◽  
Adult Patients ◽  
Severe Atopic Dermatitis ◽  
Single Center ◽  
Single Center Experience

Real‐world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records

2019 ◽  
Vol 59 (2) ◽  
pp. 253-256 ◽  
Author(s):  
Candice Wang ◽  
Christina N. Kraus ◽  
Krupa G. Patel ◽  
Anand K. Ganesan ◽  
Sergei A. Grando
Keyword(s):  
Atopic Dermatitis ◽  
Retrospective Analysis ◽  
Real World

scholarly journals Real-world effectiveness, treatment pattern, and safety of ranibizumab in Korean patients with neovascular age-related macular degeneration: Subgroup analyses from the LUMINOUS study

2020 ◽  
Author(s):  
Min Sagong ◽  
Se Joon Woo ◽  
Youkyung Lee
Keyword(s):  
Macular Degeneration ◽  
Real World ◽  
Age Related Macular Degeneration ◽  
Loading Dose ◽  
Open Label ◽  
Korean Patients ◽  
Age Related ◽  
Younger Age ◽  
Treatment Naïve ◽  
One Year

Abstract Background To evaluate the real-world effectiveness, treatment patterns, and safety of ranibizumab in Korean patients with neovascular age-related macular degeneration (nAMD). Methods LUMINOUS™ is a 5-year, global, prospective, observational, open-label study. Adults aged ≥18 years who were either treatment-naïve or prior-treated were enrolled and treated with ranibizumab 0.5 mg per the local label. Outcome measures included mean (±standard deviation) changes from baseline in visual acuity (VA) and central retinal thickness (CRT), and rate of ocular and non-ocular adverse events (AEs). Results Overall, 367 Korean patients with nAMD (152 treatment-naïve and 215 prior-treated) were enrolled. The mean VA changes from baseline at 1-year were +10.1 (±21.77; P = 0.0005) and +1.4 (±15.17; P = 0.2142) Early Treatment Diabetic Retinopathy Study letters, with mean number of injections of 5.2 and 3.4 in the treatment-naïve and prior-treated groups, respectively. VA gains were greater in patients with worse baseline VA, who received a loading dose, and with polypoidal choroidal vasculopathy (PCV). Multivariate logistic regression analyses demonstrated younger age, worse baseline VA, and those who received loading dose being associated with higher odds of any gain in VA at 1 year ( P < 0.05). Mean CRT changes from baseline were –126.7 (±174.90) µm ( P < 0.0001) and +10.8 (±89.52) µm ( P = 0.5833) in the treatment-naïve and prior-treated groups, respectively, with greater reductions observed in patients with PCV. Ocular and non-ocular AEs were reported in 8.4% (n=31) and 10.1% (n=37) of patients, respectively. Conclusion The LUMINOUS study confirms real-world effectiveness and safety of ranibizumab in Korean patients with nAMD; factors including age, baseline VA, and loading-dose were associated with VA gain at one-year post-treatment.

Sign in / Sign up

Export Citation Format

Share Document